课题基金 / 基金详情

Prescription Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]: a population-based, multi-province platform for comprehensive pharmacovigilance

Prescription Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]: a population-based, multi-province platform for comprehensive pharmacovigilance
多发性硬化症处方药安全性和有效性 [DRUMS]：基于人群的多省综合药物警戒平台
批准号：
368806
负责人：
Tremlett Helen L
金额：
$88.89万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-09-01 至 2022-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=368806&lang=en
关键词：
Chronic Disease Disability Disease Modifying Drugs Drug Effectiveness Drug Safety Health Administrative Data Multiple Sclerosis Pharmacovigilance Population-Based Post-Marketing, Real World

项目摘要

项目成果

Tremlett Helen L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Canada has one of the world's highest rates of multiple sclerosis (MS). MS is a chronic disease of the brain and spinal cord. MS often starts in young adulthood and there is no cure. The goal of our research is to find out how safe and effective the drugs
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human immunodeficiency virus, antiretroviral drugs and multiple sclerosis risk (HIV-MS)
  • 批准号：
    385764
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2018
  • 负责人：
    Tremlett Helen L
  • 依托单位：
    University of British Columbia
Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]
  • 批准号：
    367789
  • 项目类别：
    Operating Grants
  • 资助金额：
    $101.65万
  • 财政年份：
    2017
  • 负责人：
    Tremlett Helen L
  • 依托单位：
    University of British Columbia
Canada Research Chair Tier 2
  • 批准号：
    335775
  • 项目类别：
  • 资助金额：
    $36.43万
  • 财政年份：
    2015
  • 负责人：
    Tremlett Helen L
  • 依托单位：
    University of British Columbia
The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus
海外基金